What our clients say
Engaging Ichor has enabled us to variablize the fixed costs of operating a lab and dedicate our capital to scientific work. Ichor’s responsiveness and thoroughness are unmatched. We rely on their strategic guidance and competent experimental work; truly a partner rather than merely a vendor.
Ichor’s executive team has a unique talent for creative problem-solving and a goal-oriented approach to research. They have built and led several highly effective research initiatives for SENS Research Foundation, with a consistent focus on value creation and actionable endpoints.
Ichor has redefined effective implementation and quality assurance since I began working with them in 2014. Their emphasis on understanding project requirements, coupled with rigorous method development, elevate them head and shoulders above other CROs in the space.
Syracuse, NY – Ichor Therapeutics, a pre-clinical contract research organization, recently announced the appointment of Cornelis (Cees) Hendrik Wortel MD, PhD to the position of Chief Medical Officer (CMO). Dr. Wortel brings over 25 years of experience to Ichor, having worked as a senior (bio) pharmaceutical executive for early stage and established companies, both nationally […]
Philadelphia, PA and LaFayette, NY – Today, Ship of Theseus, LLC, a bioengineering company that focuses on stem cell therapies for aging and age-associated disease, announces the initiation of a murine lifespan study to be conducted at Ichor Therapeutics, Inc. This work will inform new targets for therapeutic intervention in aging. Ship of Theseus was […]
LaFayette, NY – Today, a landmark biotechnology was published for the first time in the peer-reviewed journal ACS Biochemistry. The article, “RPtag as an orally bioavailable, hyper stable epitope tag and generalizable protein binding scaffold,” describes a foundational technology that could have huge implications in drug discovery, diagnostics, and clinical antibody therapy.
Fredonia, NY: Today, the State University of New York at Fredonia hosted the Northeastern District-3 Conference for TriBeta, the Biology Honor Society. Kelsey Moody, CEO at Ichor Therapeutics, delivered the keynote address. In the address, he discussed Ichor’s humble beginnings in a West Syracuse apartment, and encouraging pre-clinical results from the company’s age-related macular degeneration […]